Morphic News Category: Press Release

AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

18 October 2018
Morphic Therapeutic
Categories: Morphic Therapeutic, Press Release

Collaboration leverages Morphic’s unique platform for developing oral integrin drugs and AbbVie’s global development and commercialization capabilities

NORTH CHICAGO, Ill. and WALTHAM, Mass. – October 18, 2018 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a research and development collaboration designed to advance a number of Morphic’s oral integrin therapeutics for fibrosis-related indications.

Read More

Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics through Clinical Proof of Concept

25 September 2018
Morphic Therapeutic
Categories: Morphic Therapeutic, Press Release

Series B financing led by Omega Funds and Novo Holdings

Financing to enable the initiation of IND-enabling and clinical studies in 2019

WALTHAM, Mass. – September 25, 2018 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that it has completed a $80 million Series B financing to fund its two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.

Read More